Intellia Therapeutics (NTLA) Treasury Shares (2015 - 2016)

Intellia Therapeutics (NTLA) has reported Treasury Shares for 12 consecutive years, with $6.3 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Treasury Shares rose 13.83% year-over-year to $6.3 million; the TTM figure through Mar 2026 stood at $6.3 million (up 13.83% YoY), while the FY2025 annual figure was $5.2 million, down 6.33% from the prior year.
• Treasury Shares climbed to $6.3 million in Q1 2026 per NTLA's latest filing, from $5.2 million in the prior quarter.
• Across five years, Treasury Shares topped out at $6.3 million in Q1 2026 and bottomed at $1.4 million in Q1 2022.
• Historically, Treasury Shares has averaged $4.3 million across 5 years, with a median of $5.2 million in 2025.
• Annual changes were most pronounced in 2022 — Treasury Shares soared 334.88% — and 2025, when it retreated 6.33%.
• Intellia Therapeutics' Treasury Shares stood at $1.9 million in 2022, then soared by 108.19% to $4.0 million in 2023, then soared by 37.26% to $5.5 million in 2024, then slipped by 6.33% to $5.2 million in 2025, then rose by 21.05% to $6.3 million in 2026.
• Business Quant data shows NTLA's Treasury Shares at $6.3 million in Q1 2026, $5.2 million in Q4 2025, and $5.2 million in Q3 2025.